The PPL trial was the worst and BTW they used transgenic protein as you know. Telecris trial which was not placebo controlled (CF patients): <a href="http://clinicaltrials.gov/ct2/show/NCT00486837?term=Alpha1-antitrypsin+inhaled&rank=2" target="_blank">http://clinicaltrials.gov/ct2/show/NCT00486837?term=Alpha1-antitrypsin+inhaled&rank=2</a> and the Baxter/Arriva which was a safety trial of inhaled recombinant alpha 1-antitrypsin in subjects with alpha 1-antitrypsin deficiency: <a href="http://clinicaltrials.gov/ct2/show/NCT00161707?term=Alpha1-antitrypsin+inhaled&rank=3" target="_blank">http://clinicaltrials.gov/ct2/show/NCT00161707?term=Alpha1-antitrypsin+inhaled&rank=3</a> Both did not continue with the inhaled program but a trend was seen and published: <a href="http://www.ncbi.nlm.nih.gov/pubmed/17050563?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank">http://www.ncbi.nlm.nih.gov/pubmed/17050563?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum</a> Kamada thinks that their ATT is better and that the Pari's device is superior. I personally think the odds are not high.